COVID-19 Neutralizing Antibody Explained

As more and more people in the United States get vaccinated against COVID-19, the number of new cases is falling each day. However, these vaccines are not 100% effective. The Pfizer-BioNTech and Moderna vaccines have efficacy rates of 94%-95%, which, while very high, still leads to the implication that, out of every 100,000 persons receiving these vaccines, 5,000 – 6,000 people will not be protected from COVID-19. This means that some individuals who receive the vaccine may be unaware they’ve failed to develop COVID-19 immunity.

The goal of the vaccines is to train the body to evoke adaptive immune response which typically produces virus specific neutralizing antibodies and T-cells. The neutralizing antibodies have been shown in the scientific literature to be able to block the virus entry and prevent infection and are expected to be good biomarker for immunity.

COVID-19 Immunity Information

  • COVID-19 Neutralizing Antibody
  • Immunity to SARS
  • Potential Use of Convalescent Plasma for SARS-CoV-2
  • Hemodialysis and Kidney Transplant Patients
  • Neutralizing Antibody Material
  • Aging, Immunity, and COVID-19
  • Lack of Immune Response after mRNA Vaccination
  • Poor Humoral and T-Cell Response to RNA Vaccine